Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan 22;48(1):56-61.
doi: 10.2478/raon-2013-0046. eCollection 2014 Mar.

Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?

Daniel E Spratt  1 , Lucas Resende Salgado  1 , Nadeem Riaz  1 , Michael G Doran  1 , Moses Tam  1 , Suzanne Wolden  1 , Evangelia Katsoulakis  1 , Shyam Rao  1 , Alan Ho  2 , Richard Wong  3 , Nancy Y Lee  1
Affiliations

Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy's local control superior?

Daniel E Spratt et al. Radiol Oncol. .

Abstract

Background: The results of RTOG-MRC randomized trial of photon (n=15) versus neutron (n=17) therapy in the 1980's reported an improved local control (LC) with neutron radiotherapy for unresectable salivary gland tumors. Due to increased severe toxicity with neutron radiotherapy and the paucity of neutron-therapy centers, we analyzed our institution's results of photon radiotherapy for unresectable salivary gland tumors.

Patients and methods: From 1990 to 2009, 27 patients with unresectable salivary gland cancer underwent definitive photon radiotherapy at our institution. Nodal involvement on presentation was found in 9 patients. Median dose of radiotherapy was 70 Gy. Chemotherapy was given to 18 patients, most being platinum-based regimens. Local control (LC), locoregional control (LRC), distant metastasis-free survival (DMFS), overall survival (OS), and toxicity outcomes were assessed.

Results: With a median follow-up of 52.4 months, the 2/5-year actuarial LC was 69% (95%CI ± 21.0%)/55% (± 24.2%), LRC was 65% (± 21.4%)/47% (± 21.6%), and DMFS was 71% (± 21.8%)/51% (± 22.8%), respectively using competing risk analysis. The median OS was 25.7 months, and the 2/5-year OS rates were 50% (± 19.0%)/29% (± 16.6%), respectively. Higher histologic grade was significant for an increased rate of DM (intermediate grade vs. low grade, p=0.04, HR 7.93; high grade vs. low grade, p=0.01, HR 13.50). Thirteen (48%) patient's experienced acute grade 3 toxicity. Late grade 3 toxicity occurred in three (11%) patients.

Conclusions: Our data compares favorably to neutron radiotherapy with fewer late complications. Photon radiotherapy is an acceptable alternative to neutron radiotherapy in patients who present with unresectable salivary gland tumors.

Keywords: IMRT; neutron; photon; radiotherapy; salivary gland cancer.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
Local failure cumulative incidence for entire cohort with death as the competing risk.
FIGURE 2.
FIGURE 2.
Loco-regional failure cumulative incidence for entire cohort with death as the competing risk.
FIGURE 3.
FIGURE 3.
Distant-metastasis cumulative incidence for the entire cohort with death as the competing risk.
FIGURE 4.
FIGURE 4.
Kaplan Meier for overall survival of entire cohort.
See this image and copyright information in PMC

References

    1. Guzzo M, Locati LD, Prott FJ, Gatta G, McGurk M, Licitra L. Major and minor salivary gland tumors. Crit Rev Oncol Hematol. 2010;74:134–48. - PubMed
    1. Mendenhall WM, Morris CG, Amdur RJ, Werning JW, Villaret DB. Radiotherapy alone or combined with surgery for salivary gland carcinoma. Cancer. 2005;103:2544–50. - PubMed
    1. Engels H, Wambersie A. Relative biological effectiveness of neutrons for cancer induction and other late effects: a review of radiobiological data. Recent Results Cancer Res. 1998;150:54–87. - PubMed
    1. Laramore GE, Krall JM, Griffin TW, Duncan W, Richter MP, Saroja KR, et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int J Radiat Oncol Biol Phys. 1993;27:235–40. - PubMed
    1. Griffin TW, Pajak TF, Laramore GE, Duncan W, Richter MP, Hendrickson FR, et al. Neutron vs photon irradiation of inoperable salivary gland tumors: results of an RTOG-MRC Cooperative Randomized Study. Int J Radiat Oncol Biol Phys. 1988;15:1085–90. - PubMed